Optimi Health Corp. (OPTH) Next Earnings Date & Expected ±12.5% Move

Per the Roarable RQD rating, OPTH scores 47 out of 100 for a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The Fundamental Cash Engine pillar scores 12 of 20, reflecting an ROIC of 0% and an FCF yield of 0%, which means the rating reports no measurable return on capital and no free cash flow yield. The Whale 13F Flow pillar scores 3 of 20 for institutional accumulation and options positioning, the weakest pillar in the set. The Insider Conviction pillar scores 9 of 20 for SEC Form 4 and Congressional PTR cluster flow. The Macro Regime Fit pillar scores 10 of 20, with a Beta of 1.0 and a sector sensitivity assessment. The Forensic Balance Sheet pillar scores 13 of 20, citing an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5. For a prospective investor, the rating's most decisive signal is the combination of zero reported profitability returns with the lowest institutional-flow score, which points to weak external conviction rather than a single isolated weakness. The balance sheet pillar is the relative bright spot, indicating the company is not flagged as financially distressed on the forensic metrics provided. Upside drivers are not identified in the rating itself; any recovery case would depend on catalysts outside the reported fundamentals, and the rating frames the present posture as distribution risk.

Optimi Health Corp. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the Profile section. Per the Profile section, the company's market capitalization is $0.0B. The source data does not detail its products, customers, or revenue model. Per the news wire, the company has reported a finished MDMA batch ahead of an Australian export and established an Australian subsidiary, Optimi Australia Pty Ltd, as a distribution and business development entity.

Per the recent news and catalysts section, all six items are tagged YELLOW with the impact label MARKET WIRE. The headlines cover an Australian subsidiary establishment, a psychedelic drug company investment item referencing SRx Health, a finished MDMA batch ahead of an Australian export, a ThinkEquity conference presentation, a commentary piece on psychedelic medicine infrastructure, and the formation of Optimi Australia Pty Ltd. Key catalysts are the Australian export and distribution build-out. Risk watch items include the market's reaction to a price decline of -6.81% and the thin float implied by a $14.9M market capitalization. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, no butterfly links are recorded, and no proprietary signals are present. Upstream and downstream dependencies cannot be mapped from the source data. Sector correlations are not quantified beyond the reported Beta of 1.0. A prospective investor should watch whether the Australian export and distribution entity converts into reported revenue, since the source data supplies no financial statements to confirm it.

• What revenue, operating income, and cash flow does the company report in its financial statements, given that the financials section is absent?
• What are the company's product candidates, regulatory status, and revenue sources behind the MDMA batch and Australian export?
• What is the actual institutional (13F) and insider (Form 4) holding picture, given that the holders section is absent?
• What are the analyst consensus ratings and price targets, given that the analyst data section is absent?
• What is the cash runway and debt maturity profile underlying the 0.5 Debt/Equity figure?